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Despite the recent progress in treatment options, malignant melanoma remains a deadly disease. Besides therapy, inherited
factors might modulate clinical outcome, explaining in part widely varying survival rates. T-cell effector function regulators on
antitumor immune responses could also influence survival. CD5, a T-cell receptor inhibitory molecule, contributes to the mod-
ulation of antimelanoma immune responses as deduced from genetically modified mouse models. The CD5 SNPs rs2241002
(NM_014207.3:c.671C> T, p.Pro224Leu) and rs2229177 (NM_014207.3:c.1412C> T, p.Ala471Val) constitute an ancestral hap-
lotype (Pro224-Ala471) that confers T-cell hyper-responsiveness and worsens clinical autoimmune outcome. The assessment
of these SNPs on survival impact from two melanoma patient cohorts (Barcelona, N5493 and Essen, N5215) reveals that
p.Ala471 correlates with a better outcome (OR5 0.57, 95% CI50.33–0.99, Adj. p50.043, in Barcelona OR50.63, 95%
CI50.40–1.01, Adj. p50.051, in Essen). While, p.Leu224 was associated with increased melanoma-associated mortality in
both cohorts (OR51.87, 95% CI51.07–3.24, Adj. p50.030 in Barcelona and OR51.84, 95% CI51.04–3.26, Adj.
p50.037, in Essen). Furthermore survival analyses showed that the Pro224-Ala471 haplotype in homozygosis improved mela-
noma survival in the entire set of patients (HR50.27, 95% CI 0.11–0.67, Adj. p50.005). These findings highlight the rele-
vance of genetic variability in immune-related genes for clinical outcome in melanoma.
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Melanoma is the most deadly of the common skin cancers in
Caucasians. To date, histological features of the primary mel-
anoma are important hallmarks of early melanoma prognosis
and staging.1 However, patients within the same tumor stage
exhibit a high variation in survival rates suggesting that other
intrinsic factors modulate outcome.2 Melanoma is highly
immunogenic, but can evade immune responses via several
mechanisms including loss of expression of Class I major his-
tocompatibility complex antigens, production of immunosup-
pressive cytokines, activation of regulatory T-cells and
expression of inhibitors for effector T cells (CTLA-4, PD-1/
PD-L1).3 Progress in understanding the relationship between
immune and tumor cells has led to the development of suc-
cessful immunotherapies targeting the so called immune
checkpoints (e.g., CTLA-4, PD-L1 and PD-1 inhibitors).4
Unfortunately, not all patients respond to these therapies and
duration and effectiveness vary among responders.5 Thus, the
identiﬁcation of new therapeutic targets and prognostic bio-
markers is essential to further improve patient care.
Accumulating clinical and experimental evidence indicates
that the T-cell modulatory properties of CD5 might play a
role in the antitumor immune response by acting as a puta-
tive immune regulator checkpoint.6,7 CD5 is a lymphoid-
speciﬁc 67 kDa receptor, mainly expressed by all T cells and
the small B1 subset involved in the production of polyreac-
tive natural antibodies.8 Even though the nature of the CD5
ligand is still a controversial matter, it is widely accepted that
CD5 is indeed a negative regulator of signaling by the clono-
typic antigen-speciﬁc receptor present on T and B1 cells9,10
to which it physically associates and co-localizes at the center
of the immune synapse.11 Noteworthy, CD5 is found to be
up-regulated in T and B cells with regulatory/suppressor
function as well as in T (either CD41 or CD81) and B cells
anergized by repeated antigen stimulation.7,8
No CD5 deﬁciencies have been reported in humans so far.
However, several coding nonsynonymous single nucleotide
polymorphisms (SNP) have been identiﬁed in the CD5
gene.12 Interestingly, the CD5 gene has been under recent
evolutive selective pressure, probably long after the ﬁrst colo-
nization of East Asia by anatomically modern humans, the
nonsynonymous SNP rs2229177 (NM_014207.3:c.1412C>T),
coding for an Ala to Val substitution at the cytoplasmic tail
of CD5 (p.Ala471Val), being the most probable target for
selection. The rs2229177 variants together with another fre-
quent SNP coding for a Pro to Leu substitution at the extrac-
ellular region of CD5 (rs2241002, NM_014207.3:c.671C>T,
p.Pro224Leu) constitute different haplotypes, one of which
(Pro224-Val471) has been positively selected in East Asian
populations.12 Functional analyses reveal that homozygous
carriers of the ancestral Pro224-Ala471 (CC) haplotype pres-
ent higher in vitro T cell proliferative responses and a more
severe clinical form of Systemic Lupus Erythematosus com-
pared to homozygous individuals for the more recently
derived Pro224-Val471 (CT) haplotype.13 This ﬁnding sug-
gests a link between differential regulation of T-cell signaling
by CD5 variants and distinct autoimmune disease outcome.
Considering that the immune system plays an opposite
role in autoimmune diseases and cancer, we addressed the
putative association between CD5 allelic variations at SNPs
rs2229177 and rs2241002 and clinical outcome of melanoma
in two independent cohorts (Barcelona N5 493 and Essen
N5 215).
Material and Methods
Design and samples
The retrospective study comprised two independent Hospital
Based series of melanoma patients. Recruitment (and there-
fore blood sampling) took place wherever possible 3–6
months after diagnosis. Patients were included in the study
when the following information was available: conﬁrmed
alive/death status at last follow-up (melanoma-speciﬁc sur-
vival), at least one update in follow-up (months) since the
date of diagnosis, sentinel lymph node biopsy result (SLN)
(positive/negative), gender (male, female), age at diagnosis
and Breslow thickness (mm). Exclusion criteria were lack of
germinal DNA sample or lack of signed informed consent.
The ﬁrst set consisted of a Hospital Based series of 493
melanoma patients from the Melanoma Unit of Hospital
Clinic of Barcelona, Spain. Patients were diagnosed with mel-
anoma between 1994 and January 2013 (median time of fol-
low-up: 43 months). Cohort disease status was established
through the annual review and review of medical notes, from
electronic records of the patients with visits every 3–4
months the ﬁrst 2 years, every 6 months until 5 years and
annual until 10 years.
The second cohort comprised a Hospital Based series of
215 melanoma patients from University Hospital Essen, Ger-
many. Patients were diagnosed with melanoma between 1982
What’s new?
Accumulating clinical and experimental evidence indicates that the T-cell modulatory properties of CD5 might play a role in
the antitumor immune response by acting as a putative immune regulator checkpoint. Here, the authors examined the associ-
ation between CD5 allelic variations at SNPs rs2229177 and rs2241002 and clinical outcome of malignant melanoma in two
independent cohorts. They found that CD5 functional variants influence melanoma outcome, illustrating the contribution of the
genetic variability of the host’s immune response on patient survival prospects. This study supports the CD5 immune check-
point as a new target for the improvement and development of new cancer immunotherapies.
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and 2009 (median time of follow-up was 46 months). The
cohort disease status was established in the same way as for
the Barcelona cohort and included an update of lost to
follow-up by phone calls.
In the Barcelona cohort, the patient’s stage at diagnosis
according to AJCC1 was: 45% Stage I (22 IA, 187 IB, 13 I
unknown ulceration status), 33% Stage II (50 IIA, 53 IIB, 17
IIC, 43 II unknown ulceration status) and 22% Stage III
(number of positive SLN or presence of micro/macro metas-
tasis was not recorded in our database, thus patients could
not be subclassiﬁed into IIIA, IIIB or IIIC). In the Essen
cohort, the patient’s stage at diagnosis according to AJCC
was: 28% Stage I (61 IB), 45% Stage II (40 IIA, 33 IIB, 11
IIC, 12 II unknown ulceration status) and 27% Stage III (24
IIIA, 16 IIIB, 5 IIIC, 13 III with unknown number of positive
SLN or presence of micro/macro metastasis). The study was
approved by the ethical committee of the Hospital Clinic of
Barcelona. The patients gave their written, informed consent.
CD5 genotyping
Genomic DNA was obtained from peripheral blood lympho-
cytes. TaqMan Genotyping Assays were used to genotype
CD5 SNPs rs2229177 (assay number: C___3237272_10) and
rs2241002 (assay number: C__25472293_20) according to the
manufacturer’s recommendations (TermoFisher, Barcelona,
Spain). The 7900HT Fast Real-Time PCR System (Applied
Biosystems, Bleiswijk, The Netherlands) was used. The results
were analyzed using the Applied Biosystems TaqMan Geno-
typer Software (TermoFisher, Barcelona, Spain).
In the Barcelona set, SNP genotyping was successful for
rs2229177 and rs2241002 in 99.4% (490/493) and 99.8%
(492/493) of patients, respectively. In Essen, both SNPs were
successfully genotyped in 99.5% (214/215) of patients. In the
two patient sets both SNPs were in Hardy–Weinberg equilib-
rium (Barcelona: rs2229177 p5 0.500 and rs2241002
p5 1.000, Essen: rs2229177 p5 1.000 and rs2241002
p5 0.370). The two CD5 SNPs analyzed were not in linkage
disequilibrium in either patient set (D05 0.597, r25 0.100
and D05 0.311, r25 0.018 in Barcelona and Essen,
respectively).
Statistical analyses
The main clinical event assessed was melanoma-speciﬁc sur-
vival. A two-sided Pearson chi-squared test was used for gen-
eral descriptive analyses for categorical variables. A t test was
used for general descriptive analyses for continuous variables.
The Breslow thickness variable did not follow the normal dis-
tribution and was transformed using the logarithm function.
The melanoma-speciﬁc survival according to different haplo-
types was assessed using Kaplan–Meier curves and backward
multivariate Cox regression analysis. The hazard ratio (HR)
and its 95% CI were calculated. SPSS 17.0 was used to per-
form descriptive statistical analyses and survival analyses.
Genotype and haplotype association analyses were performed
using the bioinformatics tool SNPStats (http://bioinfo.iconco-
logia.net/SNPstats).14 The odds ratio (OR) and its 95% CI
were calculated. Gender, SLN, age at diagnosis and log trans-
formed Breslow were included as covariates in the analyses.
Information about Ulceration was not included due to the
high number of tumors without this information in the Bar-
celona set of patients. The tests were considered signiﬁcant if
p values or adjusted p values as applicable was <0.05.
Results and Discussion
Descriptive analyses of the clinical and genetic variables
showed that the characteristics known to be associated with
worse melanoma prognosis (male gender, melanoma-death
and positive sentinel lymph node) and rs2241002 genotype
frequencies were signiﬁcantly different between the two
cohorts (Supporting Information Tables S1 and S2). The
association analysis of SNP rs2229177 with melanoma-
speciﬁc survival (Table 1) showed that the ancestral C allele
(p.Ala471) had a statistically signiﬁcant effect on melanoma
outcome in the Barcelona-cohort (OR5 0.57, 95% CI5 0.33–
0.99, Adj. p5 0.043) and a trend close to statistical signiﬁ-
cance in the Essen-cohort (OR5 0.63, 95% CI5 0.40–1.01,
adj. p5 0.051). Additionally, the minor T allele of rs2241002
(p.Leu224) was associated with increased melanoma-
associated mortality in both the Barcelona-cohort (OR5 1.87,
95% CI5 1.07–3.24, Adj. p5 0.030) and the Essen-cohort
(OR5 1.84, 95% CI5 1.04–3.26, Adj. p5 0.037).
Haplotype analyses with SNPStats showed that the pres-
ence of T alleles for both SNPs (Leu224-Val471 haplotype)
was associated with increased risk of melanoma-associated
death in the Barcelona-cohort (OR5 2.52, 95% CI5 1.22–
5.22, Adj. p5 0.013), while in Essen, the presence of the C
allele in both SNPs (Pro224-Ala471 haplotype) had a protec-
tive role on melanoma survival (OR5 0.49, 95% CI5 0.27–
0.90, Adj. p5 0.022). Thus, the ancestral CD5 Pro224-Ala471
haplotype associates with increased melanoma-speciﬁc sur-
vival, while the more recently derived Leu224-Val471 associ-
ates with reduced melanoma survival. As functional analyses
have revealed that the ancestral CD5 Pro224-Ala471 haplo-
type increases the immune activity compared with the
Pro224-Val471 haplotype,13 we assessed the melanoma-
speciﬁc survival using Kaplan–Meier and Cox regression
analyses, comparing individuals homozygous for each haplo-
type in the entire patient set (Fig. 1a). We identiﬁed that car-
riers of the Pro224-Ala471 haplotype in homozygosis have a
better survival compared with the carriers of the Pro224-
Val471 haplotype in homozygosis (HR5 0.21, 95% CI 0.07–
0.58, Adj. p5 0.003). These individuals also have a better
survival compared with other haplotype combinations
(HR5 0.27, 95% CI 0.11–0.67, Adj. p5 0.005) and also com-
pared with homozygotes for the Leu224-Val471 haplotype
(HR5 0.20, 95% CI 0.05–0.80, Adj. p5 0.022), the most
extreme haplotype combination (Fig. 1b). When AJCC stag-
ing was included in the model instead of log transformed
Breslow and SLN status, the results were similarly signiﬁcant
(data not shown).
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As patients from different stages at diagnosis (I, II and III)
were included in the study, we performed survival analyses
according to the functional Pro224-Ala471 vs. Pro224-Val471
haplotypes, grouping patients by staging (Supporting Informa-
tion Fig. S1). Although, we have not enough power to reach
signiﬁcance, a protective effect on melanoma survival of the
Pro224-Ala471 haplotype in homozygosis could be observed in
the three stages (Stage I: HR5 0.18, 95% CI 0.21–1.53, Adj
p5 0.117; Stage II: HR5 0.15, 95% CI 0.02–1.22, Adj.
p5 0.077, and Stage III: HR5 0.39, 95% CI 0.11–1.43, Adj.
p5 0.154). Thus, the effect of CD5 variants on the modulation
of melanoma outcome is independent of the stage at diagnosis.
The results represent, as far as we know, the ﬁrst report on
the impact of functional germline variants from an immune-
regulatory receptor in melanoma outcome. Previous studies
have identiﬁed SNPs from several non-immune related genes
that impact melanoma prognosis. This is the case for the GC
gene (rs2282679), linking lower serum levels of vitamin D with
increased melanoma-speciﬁc deaths,15 and for the MC1R
gene,16 for which loss of function variants up-regulate oxida-
tive stress-related pathways and DNA damage,17 favoring the
apoptosis of damaged cells. SNPs in Nucleotide Excision
Repair (NER) and Poly [ADP-Ribose] Polymerase 1 (PARP1)
genes have also been implicated in melanoma prognosis, show-
ing the relevance of the DNA damage and repair system for
tumor survival.18,19 A similar situation applies to genes from
the Hippo pathway, which control cell migration, development
and organ sizes in diverse species,20 as well as genes from the
Notch21 and Fanconi anemia22 pathways. Related with immu-
nity, SNPs in the interleukin locus and angiogenesis have also
been associated with melanoma progression.23,24
The presence of immune cells in the tumor microenviron-
ment is known to inﬂuence melanoma prognosis.25 Currently
available melanoma immunotherapies target lymphocyte
receptors involved in down-regulating T-cell effector func-
tions (e.g., CTLA-4, PD-1 and PD-1 ligand), collectively
known as “immune check-points.” In accordance with previ-
ously published studies,7 the present association study sup-
ports a role for CD5 as a new immune modulatory receptor,
which paves the way for improvement of current therapies
against melanoma. Indeed, available evidence supports the
involvement of CD5 in the regulation of antitumour immune
responses. Early mouse studies showed the efﬁcacy of a non-
depleting anti-CD5 monoclonal against lymphoid and non-
lymphoid tumors.26 Later reports found that in situ sensory
adaptation of Tumor inﬁltrate lymphocytes (TILs) from
patients undergoing lung carcinoma involves down-
regulation in CD5 surface expression.6 More recently, studies
involving CD5-deﬁcient mice6 and transgenic mice expressing
a soluble form of human CD527 showed improved anti-
tumor responses using non-orthotopic mouse melanoma
models (B16 cells).
In conclusion, the present study illustrates an unprece-
dented, although predictable, fact: the genetic variability of
the host’s immune response inﬂuences melanoma survival.
The results are also in line with a recent observation from
our group showing that rs2229177 variants impact the sur-
vival response of chronic lymphocytic leukemia patients to
conventional chemotherapy regimens.28 Thus, the identiﬁca-
tion of new inherited variants in immune-related genes may
also be useful to identify patients that are going to respond
better to available treatments.
Table 1. Genetic association of the CD5 SNPs rs2229177 and rs2241002 with melanoma-specific survival
rs2229177 (p.Ala471Val)
MAF (C allele) Genotype Frequency
Alive Dead
Alive Dead CC CT TT CC CT TT OR 95% CI Adj. P1
Barcelona (N5490) 0.48 0.36 0.24 0.48 0.28 0.12 0.47 0.41 0.57 0.33, 0.99 0.043
Essen (N5214) 0.48 0.41 0.24 0.49 0.27 0.14 0.53 0.33 0.63 0.40, 1.01 0.051
rs2241002 (p.Pro224Leu)
MAF (T allele) Genotype Frequency
Alive Dead
Alive Dead CC CT TT CC CT TT OR 95% CI Adj. P1
Barcelona (N5492) 0.23 0.34 0.59 0.36 0.05 0.47 0.37 0.16 1.87 1.07, 3.24 0.030
Essen (N5214) 0.16 0.25 0.71 0.27 0.02 0.54 0.42 0.04 1.84 1.04, 3.26 0.037
The median (range) time of follow-up in months for Barcelona alive and death patients was 42 (1–217) and 44 (3–124), respectively, and for Essen
alive and death patients was 48 (1–177) and 38 (8–244), respectively.
MAF: minor allele frequency; OR: Odds Ratio
Minor allele of rs2229177 SNP was C, while minor allele of rs2241002 was T.
The genetic model used was the log-additive.
The statistically significant results are highlighted in bold.
1p-values were adjusted by age at diagnosis, gender, log transformed Breslow and sentinel lymph node biopsy result (positive/negative).
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